Top Story

Positive CHMP opinion for Janssen's Symtuza™ for HIV

Drug is new once-daily darunavir-based single tablet regimen.

Read more

CINQAERO® is a humanised interleukin-5 (IL-5) antagonist monoclonal antibody....

Read more

CHMP recommends license for use in adults with moderate-to-severe atopic dermatitis....

Read more

GSK has announced that the US Food and Drug Administration (FDA) has approved a new subcutaneous for...

Read more

Basilea will receive an upfront payment of CHF 70 million....

Read more

Kyntheum is first and only biologic that selectively targets IL-17 receptor subunit A....

Read more

People with less survivable cancers only have a 14% chance of survival after five years....

Read more

Early detection of dementia has become worldwide health priority....

Read more

British cancer patients were found to have worse survival rates after five years....

Read more

Overall prevalence of dementia set to increase substantially by 2040....

Read more

Report said doctors may use camera apps to record particular details of patient information....

Read more